Light-activated treatment for recurring brain tumor
Part of Cancer clinical trials.
This study tests a light-activated therapy (radiodynamic therapy) using a special medicine to help treat a brain tumor that has come back after prior treatment. It may be offered after doctors decide you need further radiation for your recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and your brain tumor is a first recurrence of glioblastoma after prior surgery and treatment
- Your doctors plan more radiation for the tumor recurrence, based on a tumor board decision
- There is confirmed lab proof the tumor is recurrent glioblastoma from a tissue sample, regardless of a specific gene marker
- You can do follow-up scans (MRI, PET, or contrast CT) and you must not be pregnant or breastfeeding
- Your overall strength is good enough (Karnofsky score 60 or higher)
- You can meet safety rules for contraception and avoid certain light-sensitizing medicines before treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach that uses a light-sensitive drug and low-intensity ultrasound to make standard chemotherapy more effective for glioblastoma. If you have completed initial treatment with radiation and temozolomide without the tumor growing, you may be eligible.
This trial studies a two-step treatment for newly diagnosed high-grade glioma: first laser treatment (LITT) to target the tumor, followed by a shorter, more focused course of radiation. It may help shrink or control the tumor while limiting treatment time.
This study tests whether using special fluorescent dye during brain tumor surgery, combined with chemotherapy and radiation, helps the body's immune system fight glioblastoma (an aggressive brain cancer). Researchers will track immune markers in your blood over time to understand how these treatments work together.
This early-stage trial tests whether a new oral medication called gallium maltolate can help slow or shrink glioblastoma (a serious brain tumor) that has come back after initial treatment. The study enrolls patients who have already had standard brain tumor treatment and whose tumors are growing again.
This trial tests a new type of targeted radiation therapy for people with high-grade glioma (grade 3 or 4) that has not progressed after standard treatment. The therapy uses a radioactive substance attached to a protein that targets tumor cells, aiming to deliver radiation directly to the cancer.
This trial tests a new radiation treatment that targets tumor cells directly. It may help people with a specific type of aggressive brain tumor that has grown after standard treatments.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.